Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, has announced that it has obtained a US$250 million term loan facility from Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in life sciences and technology-related markets. The additional capital strengthens Arcus’ balance sheet and increases flexibility to rapidly advance casdatifan, its potential best-in-class HIF-2a inhibitor.
Latham & Watkins LLP represented Arcus in the transaction with a team led by transactional partners Haim Zaltzman and Mark Roeder, with associates Trevor Church, Erin Cusenbary, and Tyler Davis. Advice was also provided on corporate matters by partner John Williams; on intellectual property matters by partner Jekkie Kim, with associate Mizuna Sekine; on tax matters by partner Eric Cho; on healthcare matters by partner Betty Pang; on FDA/regulatory matters by counsel Chad Jennings; and on other transaction matters by partner Reza Mojtabaee-Zamani, with associate Kevin Zhang.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
